The 63 references in paper H. Rafrafi , M. Volkov M., A. Smirnov V., O. Galkina V., Х. Рафрафи, М. Волков М., А. Смирнов В., О. Галкина В. (2012) “СТАТУС ВИТАМИНА D И ПАТОЛОГИЯ СЕРДЕЧНО-СОСУДИСТОЙ СИСТЕМЫ У ПАЦИЕНТОВ С РАЗЛИЧНЫМИ СТАДИЯМИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК // VITAMIN D STATE AND CARDIOVASCULAR SYSTEM PATHOLOGY AT PATIENTS WITH DIFFERENT STAGES OF CHRONIC KIDNEY DISEASE” / spz:neicon:nefr:y:2012:i:1:p:80-87

1
Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int 2011;80(12):1258-1270
(check this in PDF content)
2
Владимирова ЮФ. Течение и исходы ишемической болезни сердца у больных, получающих лечение хроническим гемодиализом. Автореферат дис. ... канд. мед. Наук. СПб., 2010
(check this in PDF content)
3
Marniemi J, Alanen E, Impivaara O et al. Dietary and serum vitamins and minerals as predictors of myocardial infarction and stroke in elderly subjects. Nutr Metab Cardiovasc Dis 2005;15(3):188-197
(check this in PDF content)
4
Anderson JL, May HT, Horne BD et al. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol 2010;106(7):963-968
(check this in PDF content)
5
Xing N, L Maldonado ML, Bachman LA et al. Distinctive dendritic cell modulation by vitamin D(3) and glucocorticoid pathways. Biochem Biophys Res Commun 2002;297(3):645-652
(check this in PDF content)
6
Mathieu C, Adorini L. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med 2002;8(4):174-179
(check this in PDF content)
7
Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell 2001;104(4):503-516
(check this in PDF content)
8
Timms PM, Mannan N, Hitman GA et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM 2002;95(12):787-796
(check this in PDF content)
9
Смирнов АВ, Волков ММ, Добронравов ВА, Рафрафи Х. Фосфорно-кальциевый обмен и состояние сердечнососудистой системы у пациентов с ранними стадиями хронической болезни почек. Тер архив 2010; 6: 25-28
(check this in PDF content)
10
Li YC,Kong J, Wei M et al. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002;110:229–238
(check this in PDF content)
11
Kristal-Bohen E, Froom P, Harari G et al. Association of calcitriol and blood pressure in normotensive men. Hypertension 1997;30:1289-1294
(check this in PDF content)
12
Lind L, Hanni A, Lithell H et al. Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am J Hypertens 1995;8(9):894-901
(check this in PDF content)
13
Боровская ЕВ. Артериальное давление у больных с хронической болезнью почек v стадии, получающих лечение гемодиализом: уровень, динамика и суточный профиль: Автореф. дис. ... канд. мед. Наук. СПб., 2010.
(check this in PDF content)
14
Weishaar RE, Simpson RU. The involvement of the endocrine system in regulating cardiovascular function: emphasis on vitamin D3. Endocr Rev 1989;10(3):351-365
(check this in PDF content)
15
Bodyak N, Ayus JC, Achinger S et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A 2007;104(43):16810-16815
(check this in PDF content)
16
Mancuso P, Rahman A, Hershey SD et al. 1,25-Dihydroxyvitamin-D3 treatment reduces cardiac hypertrophy and left ventricular diameter in spontaneously hypertensive heart failure-prone (cp/+) rats independent of changes in serum leptin. J Cardiovasc Pharmacol 2008;51(6):559-564
(check this in PDF content)
17
Zittermann A, Schleithoff SS, Tenderich G et al. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 2003;41(1):105-112
(check this in PDF content)
18
García-Canton C, Bosch E, Ramírez A et al. Vascular calcification and 25-hydroxyvitamin D levels in non-dialysis patients with chronic kidney disease stages 4 and 5. Nephrol Dial Transplant 2011;26(7):2250-2256
(check this in PDF content)
19
Волков ММ, Гордеева ЛА, Смирнов АВ. Кальциноз брюшной аорты у пациентов с хронической болезнью почек. Нефрология 2009; 13 (3): 39-41
(check this in PDF content)
20
Park CW, Oh YS, Shin YS et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999;33(1):7381
(check this in PDF content)
21
Bucharles S, Barberato SH, Stinghen AE et al. Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism. Nephron Clin Pract 2011;118(4):384-391
(check this in PDF content)
22
Zadshir A, Tareen N, Pan D et al. The prevalence of hypovitaminosis D among US adults: data from the NHANES III. Ethn Dis 2005;15(4 Suppl 5):S5-97-101
(check this in PDF content)
23
Rodríguez Villarreal I, Ortega O, Gallar P et al. [Clinical and biochemical characteristics of predialysis patients in terms of 25 hydroxy vitamin D levels]. Nefrologia 2011;31(2):185-191
(check this in PDF content)
24
González EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 2004;24(5):503-510
(check this in PDF content)
25
Tolouian R, Rao DS, Goggins M et al. Seasonal variation of vitamin D in patients on hemodialysis. Clin Nephrol 2010;74(1):1924
(check this in PDF content)
26
Jean G, Charra B, Chazot C. Vitamin D deficiency and associated factors in hemodialysis patients. J Ren Nutr 2008;18(5):395-399
(check this in PDF content)
27
Del Valle E, Negri AL, Aguirre C et al. Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial Int 2007;11(3):315-321
(check this in PDF content)
28
Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease . Kidney Int 2007;71:31-3
(check this in PDF content)
29
Freundlich M, Quiroz Y, Zhang Z et al. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 2008;74(11):1394-402
(check this in PDF content)
30
Weishaar RE, Kim SN, Saunders DE, Simpson RU. Involvement of vitamin D3 with cardiovascular function. III. Effects on physical and morphological properties. Am J Physiol 1990;258(1 Pt 1):E134-142
(check this in PDF content)
31
Xiang W, Kong J, Chen S et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005;288(1):E125-132
(check this in PDF content)
32
O'Connell TD, Berry JE, Jarvis AK et al. 1,25-Dihydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy. Am J Physiol 1997;272(4 Pt 2):H1751-H1758
(check this in PDF content)
33
Raizada V, Hillerson D, Amaram JS, Skipper B. Angiotensin II-Mediated Left Ventricular Abnormalities in Chronic Kidney Disease. J Investig Med 2012;60(5):785-791
(check this in PDF content)
34
O‘Connell TD, Giacherio DA, Jarvis AK, Simpson RU. Inhibition of cardiac myocyte maturation by 1,25-dihydroxyvitamin D3. Endocrinology 1995;136(2):482-488.
(check this in PDF content)
35
Wu J, Garami M, Cheng T, Gardner DG. 1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest 1996; 97(7):1577-1588
(check this in PDF content)
36
Przybylski R, McCune S, Hollis B, Simpson RU. Vitamin D deficiency in the spontaneously hypertensive heart failure [SHHF] prone rat. Nutr Metab Cardiovasc Dis 2010;20(9):641-646
(check this in PDF content)
37
Green JJ, Robinson DA, Wilson GE et al. Calcitriol modulation of cardiac contractile performance via protein kinase C. J Mol Cell Cardiol 2006;41(2):350-359
(check this in PDF content)
38
Cioffi G, Gatti D, Adami S. Vitamin D deficiency, left ventricular dysfunction and heart failure. G Ital Cardiol (Rome) 2010;11(9):645-653
(check this in PDF content)
39
Milovanovic M, Pesic G, Nikolic V et al. Vitamin d deficiency is associated with increased IL-17 and TNFα levels in patients with chronic heart failure. Arq Bras Cardiol 2012;98(3):259-265
(check this in PDF content)
40
Rienstra M, Cheng S, Larson MG et al. Vitamin D status is not related to development of atrial fibrillation in the community. Am Heart J 2011;162(3):538-541
(check this in PDF content)
41
Targher G, Bertolini L, Padovani R et al. Serum 25-hydroxyvitamin D3 concentrations and carotid artery intima-media thickness among type 2 diabetic patients. Clin Endocrinol (Oxf) 2006; 65(5):593-597
(check this in PDF content)
42
Choi AI, Lo JC, Mulligan K et al. Association of vitamin D insufficiency with carotid intima-media thickness in HIV-infected persons. Clin Infect Dis 2011;52(7):941-944
(check this in PDF content)
43
Волков ММ, Дегтерева ОА, Смирнов АВ, Шевякова ЕВ, Панина ИЮ, Трофименко ИИ. Атеросклероз как основной фактор кальциноза клапанного аппарата сердца в додиализном периоде хронической болезни почек. Нефрология 2007; 11(4): 47-54
(check this in PDF content)
44
Волков ММ, Смирнов АВ, Добронравов ВА, Дегтерева ОА, Шевякова ЕВ, Панина ИЮ, Трофименко ИИ. Кальциноз сердечных клапанов у пациентов с хронической болезнью почек: связь с клинико-биохимическими показателями и влияние на внутрисердечную гемодинамику. Клин мед 2009; 87(6): 31-35
(check this in PDF content)
45
Волков ММ, Галкина ОВ, Бурдаева ЯВ, Жлоба АА, Эмануэль ВЛ. Значимость определения 25(OH)- и 1,25(OH)2- витамина D у пациентов с хронической болезнью почек в додиализном периоде. Ученые записки СПбГМУ им. акад. И.П.Павлова 2008 XV (1) 41-45
(check this in PDF content)
46
Смирнов АВ, Волков ММ, Добронравов ВА. Кардиопротективные эффекты D-гормона: обзор литературы и собственные данные. Нефрология 2009; 13(1):30-38
(check this in PDF content)
47
Shroff R, Egerton M, Bridel M et al. A bimodal association of vitamin D levels and vascular disease in children on dialysis. J Am Soc Nephrol 2008;19(6):1239-1246
(check this in PDF content)
48
Zittermann A, Schleithoff SS, Koerfer R. Vitamin D and vascular calcification. Curr Opin Lipidol 2007;18(1):41-46
(check this in PDF content)
49
Razzaque MS. The dualistic role of vitamin D in vascular calcifications. Kidney Int 2011;79(7):708-714
(check this in PDF content)
50
Aoshima Y, Mizobuchi M, Ogata H et al. Vitamin D receptor activators inhibit vascular smooth muscle cell mineralization induced by phosphate and TNF-α. Nephrol Dial Transplant 2012; 27(5):1800-1806
(check this in PDF content)
51
Rebsamen MC, Sun J, Norman AW, Liao JK. 1alpha,25dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ Res 2002;91(1):17-24
(check this in PDF content)
52
Cardus A, Parisi E, Gallego C et al. 1,25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. Kidney Int 2006;69(8):1377-1384
(check this in PDF content)
53
Yamamoto T, Kozawa O, Tanabe K et al. 1,25-dihydroxyvitamin D3 stimulates vascular endothelial growth factor release in aortic smooth muscle cells: role of p38 mitogen-activated protein kinase. Arch Biochem Biophys 2002;398(1):1-6
(check this in PDF content)
54
Cardus A, Panizo S, Parisi E et al. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007; 22(6):860-866
(check this in PDF content)
55
Thomas GN, O Hartaigh B, Bosch JA et al. Vitamin D levels predict all-cause and cardiovascular disease mortality in subjects with the metabolic syndrome: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Diabetes Care 2012; 35(5):1158-1164
(check this in PDF content)
56
Schöttker B, Ball D, Gellert C, Brenner H. Serum 25-hydroxyvitamin D levels and overall mortality. A systematic review and meta-analysis of prospective cohort studies. Ageing Res Rev 2012 Feb 17 [Epub ahead of print]
(check this in PDF content)
57
Pilz S, Iodice S, Zittermann A et al. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis 2011;58(3):374-382
(check this in PDF content)
58
Santoro D, Gitto L, Ferraro A et al. Vitamin D status and mortality risk in patients with chronic kidney disease. Ren Fail 2011; 33(2):184-191
(check this in PDF content)
59
Ravani P, Malberti F, Tripepi G et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 2009;75(1):88-95
(check this in PDF content)
60
Krause R, Schober-Halstenberg HJ, Edenharter G et al. Vitamin D status and mortality of German hemodialysis patients. Anticancer Res 2012; 32(1):391-395
(check this in PDF content)
61
Fiedler R, Dorligjav O, Seibert E et al. Vitamin D Deficiency, Mortality, and Hospitalization in Hemodialysis Patients with or without Protein-Energy Wasting. Nephron Clin Pract 2011;119(3): 220-226
(check this in PDF content)
62
Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008;168(4):397403
(check this in PDF content)
63
Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005;16(4):1115-1125 Поступила в редакцию 08.06.2012 г.
(check this in PDF content)